T cell dependence of chronic destructive murine arthritis induced by repeated local activation of toll-like receptor-driven pathways: Crucial role of both interleukin-1β and interleukin-17

Arthritis and Rheumatism

Volumn 58, Issue 1, 2008, Pages 98-108

  Joosten, Leo A B ^a   Abdollahi Roodsaz, Shahla ^a   Heuvelmans Jacobs, Marleen ^a   Helsen, Monique M A ^a   Van Den Bersselaar, Liduine A M ^a   Oppers Walgreen, Birgitte ^a   Koenders, Marije I ^a   Van Den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 23; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CELL WALL; BONE DESTRUCTION; CARTILAGE DEGENERATION; CHRONIC ARTHRITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; HELPER CELL; JOINT DESTRUCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STREPTOCOCCUS PYOGENES; T LYMPHOCYTE; TH17 CELL;

ACUTE DISEASE; ANIMALS; ARTHRITIS, INFECTIOUS; B-LYMPHOCYTES; BACTERIAL OUTER MEMBRANE PROTEINS; CARTILAGE; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; INTERLEUKIN-17; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; STREPTOCOCCUS PYOGENES; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38149108323     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23152     Document Type: Article

References (49)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
2. Goronzy JJ, Weyand CM. Rheumatoid arthritis. Immunol Rev 2005;204:55-73.
3. Andreakos E, Sacre S, Foxwell BM, Feldmann M. The toll-like receptor-nuclear factor κB pathway in rheumatoid arthritis. Front Biosci 2005;10:2478-88.
4. Ospelt C, Neidhart M, Gay RE, Gay S. Synovial activation in rheumatoid arthritis. Front Biosci 2004;9:2323-34.
5. Corr M. The Tolls of arthritis [editorial]. Arthritis Rheum 2005;52:2233-6.
6. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-80.
7. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76.
8. Seibl R, Birchler T, Loeliger S, Hossle JP, Gay RE, Saurenmann T, et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003;162:1221-7.
9. Radstake TR, Roelofs MF, Jenniskens YM, Oppers-Walgreen B, van Riel PL, Barrera P, et al. Expression of Toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-γ. Arthritis Rheum 2004;50:3856-65.
10. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprang T, van den Hoogen FH, et al. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005;52:2313-22.
11. O'Neill L. The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence. Biochem Soc Trans 2000;28:557-63.
12. Dunne A, O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003;171:re3.
13. Beg AA. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol 2002;23:509-12.
14. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005;115:2223-33.
15. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis [review]. Arthritis Rheum 1995;38:151-60.
16. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
17. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50:277-90.
18. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin-1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20.
19. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
20. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials [published erratum appears in JAMA 2006;295:2482]. JAMA 2006;295:2275-85.
21. Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:746-52.
22. Dinarello CA. Biological basis for interleukin-1 in disease. Blood 1996;87:2095-147.
23. Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov 2004;3:330-9.
24. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005;201:1355-9.
25. Andrei C, Dazzi C, Lotti L, Torrisi MR, Chimini G, Rubartelli A. The secretory route of the leaderless protein interleukin 1β involves exocytosis of endolysome-related vesicles. Mol Biol Cell 1999;10:1463-75.
26. Dinarello CA. Unraveling the NALP-3/IL-1β inflammasome: a big lesson from from a small mutation. Immunity 2004;20:243-4.
27. Tschopp JF, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol 2003;4:95-104.
28. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006;203:1685-91.
29. Plater-Zyberk C, Joosten LA, Helsen MM, Hepp J, Baeuerle PA, van den Berg WB. GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann Rheum Dis 2007;66:452-7.
30. Kuiper S, Joosten LA, Bendele AM, Edwards CK III, Arntz OJ, Helsen MM, et al. Different roles of tumour necrosis factor α and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine 1998;10:690-702.
31. Joosten LA, Koenders MI, Smeets RL, Heuvelmans-Jacobs M, Helsen MM, Takeda K, et al. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J Immunol 2003;171:6145-53.
32. Van den Broek MF, van den Berg WB, van de Putte LB, Severijnen AJ. Streptococcal cell wall-induced arthritis and flare-up reaction in mice induced by homologous or heterologous cell walls. Am J Pathol 1988;133:139-49.
33. Van den Broek MF, Hogervorst EJ, van Bruggen MC, van Eden W, van der Zee R, van den Berg WB. Protection against streptococcal cell wall-induced arthritis by pretreatment with the 65-kD mycobacterial heat shock protein. J Exp Med 1989;170:449-66.
34. Horai R, Asano M, Sudo K, Kanuka H, Suzuki M, Nishihara M, et al. Production of mice deficient in genes for interleukin (IL)-1 α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 1998;187:1463-75.
35. Cromartie WJ, Craddock JG, Schwab JH, Anderle SK, Yang C. Arthritis in rats after systemic injection of streptococcal cell or cell wall. J Exp Med 1977;146:1585-602.
36. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE, et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005;167:141-9.
37. Van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995;38:164-72.
38. Van de Loo AAJ, van den Berg WB. Effects of murine recombinant interleukin 1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 1990;49:238-45.
39. Nambu A, Nakae S, Iwakura Y. IL-1β, but not IL-1α, is required for antigen-specific T cell activation and the induction of local inflammation in the delayed-type hypersensitivity responses. Int Immunol 2006;18:701-12.
40. Haukness HA, Tanz RR, Thomson RB Jr, Pierry DK, Kaplan EL, Beall B, et al. The heterogeneity of endemic community pediatric group a streptococcal pharyngeal isolates and their relationship to invasive isolates. J Infect Dis 2002;185:915-20.
41. Weyand CM, Goronzy JJ. T cell-targeted therapies in rheumatoid arthritis. Nat Clin Pract Rheumatol 2006;2:201-10.
42. Lohr J, Knoechel B, Wang JJ, Villarino AV, Abbas AK. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med 2006;203:2785-91.
43. Rangachari M, Mauermann N, Marty RR, Dirnhofer S, Kurrer MO, Komnenovic V, et al. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med 2006;203:2009-19.
44. Burchill MA, Nardelli DT, England DM, DeCoster DJ, Christopherson JA, Callister SM, et al. Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with Borrelia burgdorferi. Infect Immun 2003;71:3437-42.
45. Coeshott C, Ohnemus C, Pilyavskaya A, Ross S, Wieczorek M, Kroona H, et al. Converting enzyme-independent release of tumor necrosis factor α and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc Natl Acad Sci U S A 1999;96:6261-6.
46. O'Sullivan BJ, Thomas HE, Pai S, Santamaria P, Iwakura Y, Steptoe RJ, et al. IL-1 β breaks tolerance through expansion of CD25+ effector T cells. J Immunol 2006;176:7278-87.
47. Nuki G, Bresnihan B, Bear MB, McCabe D, for the European Group of Clinical Investigators. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:2838-46.
48. Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 2007;66:842-3.
49. Alten RH, Pohl CC, Batard YY, Wright AA, Gram HH, Bobadilla MM, et al. ACR 20/50/70 responses in methotrexate-resistant rheumatoid arthritis patients in a double-blind, placebo-controlled phase I/II evalution of the pharmacokinetics/pharmacodynamics, safety, and preliminary efficacy of a fully human anti-IL-1β monoclonal antibody ACZ885 [abstract]. Ann Rheum Dis 2006;65 Suppl II:60.